China has started tracking down some of its citizens living abroad to collect taxes, surprising expatriates who never had to pay levies back home on overseas income, people familiar with the matter said.
State-owned enterprises operating in Hong Kong, which has one of the lowest tax rates in the world, have told Chinese expats to declare their income for last year so that they can pay taxes at home, said the people, who asked not be named because they are not authorized to speak publicly on the matter.
Chinese state-owned enterprises are also informing employees working in other nations, such as Singapore, two of the people said.
China, which charges taxes of as high as 45 percent, revised its income tax rules in January last year to help authorities start collecting money from its citizens worldwide — similar to what the US does with Americans living abroad, but Beijing only disclosed detailed instructions this year on how to file such taxes, catching many expatriates flat-footed.
The move signals the beginning of what could be a major shakeup for one of the largest expat communities in the world, as some could see their tax bills soar.
Though specific statistics on expats were not immediately available, Chinese state media have reported that there are about 60 million Chinese living overseas.
There are about 80,000 to 150,000 Chinese working in Hong Kong, the South China Morning Post said, which earlier reported on the taxation issue.
Chinese working in Macau have also been told to start paying income taxes back home, the Nikkei Asian Review reported.
The Chinese State Taxation Administration did not immediately respond to a fax seeking comment.
The move could be a big blow for Chinese expats working in places such as Hong Kong, who have only had to pay a maximum of 15 percent of their salaries in taxes. That is one-third of China’s highest tax bracket.
Apple Inc might make one out of four iPhones in India by 2025, JPMorgan & Chase Co analysts said yesterday, as the tech giant moves some production away from China, amid mounting geopolitical tensions and strict COVID-19 lockdowns in the country. JPMorgan expects Apple to move about 5 percent of iPhone 14 production from late this year to India, which is the second-biggest smartphone market in the world after China. It is also estimating that about 25 percent of all Apple products, including Mac, iPad, Apple Watch and AirPods, would be manufactured outside China by 2025 from 5 percent currently. The US company
HEADING SOUTH: The US company chose Kaohsiung as its site as more customers, partners and start-ups have expanded their operations to the southern city Qualcomm Inc yesterday inaugurated a new innovation center in Kaohsiung as it steps up efforts to foster local start-ups and a 5G technology ecosystem in the city, following in the footsteps of its local partners. The US chip company’s move fits the Kaohsiung City Government’s plan to build a semiconductor supply chain within the next five years, highlighted by Taiwan Semiconductor Manufacturing Co’s (TSMC, 台積電) first chip plant in the city. TSMC plans to start building the factory by the end of this year, and to start production of 28-nanometer and 7-nanometer chips there in 2024. Qualcomm said it had been
SLUMPING DEMAND: Inventory has climbed by up to 12 weeks as suppliers are under mounting pressure to offload excessive reserves, a TrendForce report said The price of DRAM chips is expected to fall at a steeper rate of 13 to 18 percent next quarter, as high inflation continues to weigh on demand for consumer electronics, causing chip inventories to soar, market researcher TrendForce Corp (集邦科技) said yesterday. The downtrend in DRAM prices could extend from a quarterly decline of 10 to 15 percent in the third quarter, the Taipei-based researcher said. “Demand for consumer electronics continued to stagnate during the third quarter, which used to be a high demand season,” TrendForce said in a statement. “During the quarter, memorychip consumption and shipments both showed quarterly
GlaxoSmithKline (GSK) in July made its consumer health products division a separate entity as it transforms into a world-leading biopharmaceutical company. By uniting science, technology and talent, the company is aiming to prevent and treat diseases with innovative vaccines, specialty pharmaceuticals and general medicines. GSK’s headquarters annually invests NT$192 billion (US$6.07 billion) in research and development, focusing on immune science and advanced technologies in human genetics. GSK’s drug and vaccine development focuses on infectious diseases, HIV, oncology and immunology. Investing in clinical trial research each year, GSK also brings drug development to Taiwan. It cooperates with 17 medical institutes and research